

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number	09441140
	Filing Date	1999-11-16
	First Named Inventor	Beka SOLOMON
	Art Unit	1649
	Examiner Name	<del>G. S. Ench</del> K. Ballard
	Attorney Docket Number	SOLOMON1R

## U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09441140
Filing Date	1999-11-16
First Named Inventor	Beka SOLOMON
Art Unit	1649
Examiner Name	<del>Eric</del> K. Ballard
Attorney Docket Number	SOLOMON1R

1	Bacsai et al., "Imaging of Amyloid- $\beta$ Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy", Nature Medicine, 7:369-372 (2001)	<input type="checkbox"/>
2	Bard et al., "Epitope and Isotype Specificities of Antibodies to $\beta$ -Amyloid Peptide for Protection Against Alzheimer's Disease-like Neuropathology", Proc. Natl. Acad. Sci. USA, 100:2023-2028 (2003)	<input type="checkbox"/>
3	Bard et al., "Peripherally Administered Antibodies Against Amyloid $\beta$ -Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease", Nature Medicine, 6:916-919 (2000)	<input type="checkbox"/>
4	Bickel et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against (A4 Protein: A Potential Probe for Alzheimer's Disease", Bioconjugate Chem., 5:119-125 (1994)	<input type="checkbox"/>
5	DeMattos et al., "Peripheral Anti-A $\beta$ Antibody Alters CNS and Plasma A $\beta$ Clearance and Decreases Brain A $\beta$ Burden in a Mouse Model of Alzheimer's Disease", Proc. Natl. Acad. Sci. USA, 98:88-50-8855 (2001)	<input type="checkbox"/>
6	FRASER et al., "Morphology and antibody recognition of synthetic beta-amyloid peptides," J Neurosci Res 28 (4):474-485 (1991)	<input type="checkbox"/>
7	Frenkel et al., "High Affinity Binding of Monoclonal Antibodies to the Sequential Epitope EFRH of $\beta$ -Amyloid Peptide is Essential for Modulation of Fibrillar Aggregation", Journal of Neuroimmunology, 95:136-142 (1999)	<input type="checkbox"/>
8	Johnson-Wood et al., "Amyloid Precursor Protein Processing and A $\beta$ 42 Deposition in a Transgenic Mouse Model of Alzheimer Disease", Proc. Natl. Acad. Sci. USA, 94:1550-1555 (1997)	<input type="checkbox"/>
9	SIMPSON et al., "Autoantibodies to Alzheimer and normal brain structures from virus-transformed lymphocytes. J Neuroimmunol 13(1):1-8 (1986)	<input type="checkbox"/>
10	Solomon et al., "Disaggregation of Alzheimer $\beta$ -Amyloid by Site-Directed mAb", Proc. Natl. Acad. Sci. USA, 94:4109-4112 (1997)	<input type="checkbox"/>
11	Solomon et al., "The Amino Terminus of the $\beta$ -Amyloid Peptide Contains an Essential Epitope for Maintaining its Solubility", in Progress in Alzheimer's and Parkinson's Diseases, Fisher et al., ed., Plenum Press, New York, 205-211 (1998)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09441140
Filing Date	1999-11-16
First Named Inventor	Beka SOLOMON
Art Unit	1649
Examiner Name	<del>C. C. Ender</del> K. Ballard
Attorney Docket Number	SOLOMON1R

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Kimberly Ballard/	Date Considered	02/03/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.